DRUG COST ANALYSIS ON NATIONAL HEALTH INSURANCE ERA IN HEALTH SUPPORT FACILITIES
Objective: In national health insurance (JKN) era, pharmacy can play roles in the form of behind refer pharmacies, or networking pharmacy and clinic pharmacy pratama. Behind refer pharmacies drug cost can be claimed directly to BPJS, meanwhile for the other type of pharmacy have to negotiation first with the primary health care. Drug cost variations in the JKN era affect the profitability of the business pharmacies. This research aims to the drug percentage charges against capitation and variety of drug costs.
Methods: This research is analytic observational cross-sectional. This research uses secondary data from a JKN prescription patient. This research was conducted on 6 affiliated pharmacies, 6 networking pharmacies, and 7 clinical pharmacy pratama in DIY. The sampling in this research is by purposive with 8.430 prescriptions. Data drug costs JKN era was analyzed by descriptive statistics and comparative test (Kruskal Wallis test).
Results: The result showed that average percentage of drug costs for capitation fee in the networking pharmacy is 13.58% and primary health care is 15.91%. Pharmacy in JKN era has drug cost variations (p=0.000). Drug cost in JKN era depends on the pattern of play roles with the health facilities and BPJS. The average percentage of drug costs against capitation health facilities in networking pharmacy is lower than clinical pharmacy pratama.
Conclusions: Drug costs in an era of JKN depending on the pattern of cooperation with health facilities pharmacies and BPJS. The average percentage of the cost of drugs to the pharmacy capitation health facilities in networking lower than clinic pharmacy pratama. Differences in drug costs JKN era influenced by the long days of drug administration, the number of prescription sheets, margin.
Keywords: Drug cost analysis, National health insurance (JKN), Pharmacy, Primary health care, Capitation.
2. Chandra EN. Book Practical guide networking health facilities first level pharmacy, Jakarta: The Social Security Administrator (BPJS),
3. Flynn KE, Smith MA, Davis MK. From physician to consumer: The effectiveness of strategies to manage health care utilization. Med Care Res Rev 2002;59(4):455-81.
4. Isnaini, N., Analysis of utilization antibiotic prescription for outpatient first level in the health centre Tebet, South Jakarta at 2015, J Kesehatan Masyarakat Nasional,. 2007;1(6):266-74.
5. Health Ministry, health minister regulation Republic Indonesia no 71
2013, on health care in the health insurance national, Jakarta, Health
Ministry Republic Indonesia: 2013.
6. Health Ministry, health minister regulation Republic Indonesia no 59,
2014, standard rate of health services organization on national health program, Jakarta, Health Ministry Republic Indonesia; 2014.
7. Martiningsih, D. The influence of variation payment methods capitation to the doctor of cost efficiency and quality of service. J Kedokteran Ind,
8. Pracht EE, Moore WJ. Interest groups and state Medicaid drug programs. J Health Polit Policy Law 2003;28(1):9-39.
9. World Health Organization. Pharmaceutical benefits in insurance programs. MDS-3: Managing Access to Medicines and Health Technologies. 3rd ed. Geneva: WHO; 2012. p. 22.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.